Suven Life Sciences Ltd. from Hyderabad had announced the grant of one product patent from Mexico (No: 325948 and Title: Bicyclic compounds as ligands of the nicotinic receptor beta 2 acetylcholine alpha 4) and one product patent from Singapore (No: 180674 and Title: Bicyclic compounds as alpha-4-beta-2 nicotinic acetylcholine receptor ligands) that cover New Chemical Entities (NCEs) for the treatment of neurodegenerative disorders. The NCEs belong to the class of selective alpha-4-beta-2 compounds, being developed as therapeutic agents for major depressive disorders (MDD).